# 2025年12月31日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 基于电子健康记录的持续低氧血症中重度急性呼吸窘迫综合征分类器研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41467760)
**期刊：** Critical care medicine
**PMID：** 41467760
**DOI：** 10.1097/CCM.0000000000007007

### 第一部分 原文与翻译

**英文原标题：** An Electronic Health Record-Based Classifier for Moderate-to-Severe Acute Respiratory Distress Syndrome With Persistent Hypoxemia.

> **英文摘要：**
> OBJECTIVES: To characterize the performance of an electronic health record (EHR) data-based classifier of persistent moderate-to-severe acute respiratory distress syndrome (ARDS).
> 
> DESIGN: Retrospective observational study.
> 
> SETTING: Six ICUs from two health systems.
> 
> PATIENTS: We included adults receiving greater than or equal to 24 hours of invasive mechanical ventilation (IMV) with a Pao2/Fio2 of less than or equal to 150 mm Hg on Fio2 greater than or equal to 0.6 in the first 72 hours of IMV. We evaluated classifier performance in two temporally and geographically distinct cohorts: a development cohort including patients in one of two academic medical or three mixed community ICUs in the first 3 months of 2021 or in 2022-2023, and a validation cohort from a different academic medical ICU in 2017.
> 
> INTERVENTIONS: None.
> 
> MEASUREMENTS AND MAIN RESULTS: In both cohorts, study physicians assessed patients for clinical ARDS criteria. We retrospectively applied the EHR classifier, which required a persistent Pao2/Fio2 of less than or equal to 150 mm Hg or receipt of interventions to address severe hypoxemia (i.e., prone positioning, neuromuscular blockade, inhaled pulmonary vasodilators) in the 24 hours after initially meeting hypoxemia criteria. We also evaluated classifier definitions that used peripheral oxygen saturation (Spo2)/Fio2 of less than or equal to 162 to indicate persistent hypoxemia. Of 924 patients in the development cohort, 504 (55%) had clinician-adjudicated ARDS. Of 90 patients in the validation cohort, 48 (53%) had clinician-adjudicated ARDS. In the development and validation cohorts, the primary EHR-based classifier identified 382 and 38 patients as having persistent moderate-to-severe ARDS, respectively (positive predictive value [PPV], 71%; 95% CI, 66-75% and PPV, 66%; 95% CI, 50-81%). When Spo2/Fio2 was used as the second hypoxemia marker more patients were classified as ARDS in both development and validation cohorts but with lower PPVs (67% and 62%, respectively.).
> 
> CONCLUSIONS: An EHR-based classifier using readily available data had acceptable performance for identifying patients with persistent moderate-severe ARDS. This open-source tool could be used for retrospective or prospective identification of this vulnerable population for research and quality improvement initiatives.

> **中文摘要：**
> 研究目的：旨在描述一种基于电子健康记录（EHR）数据的持续性中重度急性呼吸窘迫综合征（ARDS）分类器的性能。
> 
> 研究设计：回顾性观察研究。
> 
> 研究环境：来自两个医疗系统的六个重症监护病房（ICU）。
> 
> 研究对象：纳入在接受有创机械通气（IMV）后72小时内，其吸入氧浓度（Fio2）≥0.6，且动脉血氧分压/吸入氧浓度比值（Pao2/Fio2）≤150 mm Hg，并接受IMV时间≥24小时的成年患者。研究在两个时间与地域上独立的队列中评估分类器表现：开发队列包括2021年前3个月或2022–2023年期间来自两个学术性或三个混合型社区ICU的患者，验证队列来自另一家学术医学ICU的2017年患者。
> 
> 干预措施：无。
> 
> 测量与主要结果：在两组研究队列中，研究医生均依据临床标准评估患者是否符合ARDS诊断。随后研究者回顾性应用EHR分类器，该分类器要求患者在初次符合低氧血症标准后24小时内仍保持Pao2/Fio2 ≤150 mm Hg，或接受了针对重度低氧血症的干预措施（如俯卧位、神经肌肉阻滞剂、吸入性肺血管扩张剂）。此外，还评估了使用外周血氧饱和度/吸入氧浓度比值（Spo2/Fio2）≤162作为持续性低氧血症指标的定义。在开发队列的924名患者中，504例（55%）由临床医生判定为ARDS；验证队列的90名患者中，有48例（53%）被判定为ARDS。在开发与验证队列中，主要的EHR分类器分别识别出382例与38例持续性中重度ARDS患者（阳性预测值[PPV]分别为71%［95%置信区间66–75%］和66%［95%置信区间50–81%］）。当以Spo2/Fio2作为替代的低氧指标时，两队列中被判定为ARDS的患者更多，但PPV较低（分别为67%和62%）。
> 
> 结论：基于现成EHR数据建立的分类器在识别持续性中重度ARDS患者方面表现可接受。该开源工具可用于科研或质量改进项目中针对该高危人群的回顾性或前瞻性识别。

### 第二部分 AI 大师评价

本研究旨在验证一种基于电子健康记录的分类器是否能有效识别持续低氧血症状态下的中重度ARDS患者。通过回顾性分析两组独立ICU数据，该方法在开发与验证队列中均表现出较好的阳性预测值。研究显示，利用常规EHR数据识别ARDS具备可行性和一定准确性。此外，使用Spo2/Fio2指标可扩大识别范围，但会降低准确度。总体而言，该分类器为ARDS研究与质量改进提供了高效、标准化的自动识别途径，但仍需前瞻性验证其临床应用价值。

---

## 2. 嵌合抗原受体T细胞治疗患者在重症监护病房的入科、管理与结局的六年趋势分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41467744)
**期刊：** Critical care medicine
**PMID：** 41467744
**DOI：** 10.1097/CCM.0000000000007000

### 第一部分 原文与翻译

**英文原标题：** Six-Year Trends in ICU Admission, Management, and Outcomes of Chimeric Antigen Receptor T-Cell Patients in the ICU.

> **英文摘要：**
> OBJECTIVES: To evaluate evolving management, ICU admission, and outcomes for critically ill chimeric antigen receptor (CAR) T-cell patients over a 6-year period.
> 
> DESIGN: Multicenter retrospective cohort study from January 2018 to September 2023.
> 
> SETTING: Eight U.S. centers.
> 
> PATIENTS: Adult CAR T-cell patients requiring ICU admission.
> 
> INTERVENTIONS: None.
> 
> METHODS: Summary statistics included mean, sd, median, and interquartile range (IQR). Fisher exact test or chi-square test were used to evaluate association between year treated and other categorical variables. Cochran-Armitage test was performed to assess significance of trends across years. Multivariable logistic regression was performed to assess covariates associated with mortality.
> 
> MEASUREMENTS AND MAIN RESULTS: Demographics, toxicity management, ICU admission, support modalities, toxicity severity, and survival (ICU, hospital, and 3-mo) were compared year-to-year. From 2018 to 2023, 2238 patients received CAR T cells, with increasing number of patients treated yearly; 398 (17.8%) required ICU care. Of those admitted to the ICU, 66.1% were male, 89.2% had lymphoma, and median age was 64 years (53-71 yr). ICU admission rates declined from 38.5% (95% CI, 31.6-45.8%) in 2018 to 16.4% in 2023 (95% CI, 13.5-19.7%; p < 0.0001). Cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome was the reason for ICU admission in 87.9%. In 2023 vs. 2018, ICU patients were older (median, 65 yr [IQR, 55-73 yr] vs. 58 yr [48-67 yr]; p = 0.003) with higher comorbidity indices (4 [4-6] vs. 3 [2-4]; p = 0.005) and more severe toxicities (≥ grade 3: 90.1% vs. 69.9%; p = 0.004). Corticosteroid use for less severe toxicities (≤ grade 2 toxicity: 73.8% vs. 40.6%; p = 0.0001) and anakinra use (56% vs. 5.5%; p < 0.0001) increased throughout the years. Mortality from cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome remained low (5.5%). Age, Sequential Organ Failure Assessment greater than or equal to 10 at ICU admission, and ICU admission for noncytokine release/neurotoxicity syndrome reasons were associated with hospital mortality (odds ratios, 1.02 [95% CI, 1-1.04; p = 0.046], 4.69 [2.44-9.01; p < 0.0001], and 3.74 [1.91-7.3; p = 0.0001], respectively).
> 
> CONCLUSIONS: ICU admission rates after CAR T-cell treatment are declining. Although ICU patients are older with higher severity of illness and toxicity grades, ICU mortality after CAR T-cell therapy remains low.

> **中文摘要：**
> 研究目的：评估在6年期间重症嵌合抗原受体（CAR）T细胞患者的ICU入院、管理和结局的演变趋势。
> 
> 研究设计：2018年1月至2023年9月进行的多中心回顾性队列研究。
> 
> 研究场所：美国八个中心。
> 
> 研究对象：需入住ICU的成年CAR T细胞治疗患者。
> 
> 干预措施：无。
> 
> 研究方法：总结性统计包括均值、标准差、中位数和四分位距（IQR）。使用Fisher精确检验或卡方检验评估治疗年份与其他分类变量间的关系。采用Cochran-Armitage检验评估跨年份趋势的显著性。多变量逻辑回归用于评估与死亡率相关的协变量。
> 
> 测量与主要结果：逐年比较人口学特征、毒性管理、ICU入院情况、支持方式、毒性严重程度及生存率（ICU内、住院期及3个月）。2018年至2023年期间共有2238例患者接受CAR T细胞治疗，治疗例数逐年增加；其中398例（17.8%）需ICU治疗。在ICU患者中，66.1%为男性，89.2%患有淋巴瘤，中位年龄为64岁（53–71岁）。ICU入院率从2018年的38.5%（95% CI，31.6–45.8%）下降至2023年的16.4%（95% CI，13.5–19.7%；p < 0.0001）。87.9%的ICU入院原因为细胞因子释放综合征或免疫效应细胞相关神经毒性综合征。相比2018年，2023年ICU患者年龄更大（中位数65岁[IQR，55–73岁] vs. 58岁[48–67岁]; p = 0.003），合并症指数更高（4 [4–6] vs. 3 [2–4]; p = 0.005），且毒性更重（≥3级：90.1% vs. 69.9%; p = 0.004）。针对轻中度毒性（≤2级）使用糖皮质激素的比例（73.8% vs. 40.6%；p = 0.0001）及阿那白滞素(anakinra)的应用率（56% vs. 5.5%；p < 0.0001）均逐年上升。由细胞因子释放综合征及免疫效应细胞相关神经毒性综合征导致的死亡率保持低水平（5.5%）。年龄、ICU入院SOFA评分≥10以及因非细胞因子释放/神经毒性原因入ICU与住院死亡率显著相关（比值比分别为1.02 [95% CI，1–1.04; p = 0.046]，4.69 [2.44–9.01; p < 0.0001]，及3.74 [1.91–7.3; p = 0.0001]）。
> 
> 结论：CAR T细胞治疗后的ICU入院率呈下降趋势。尽管ICU患者年龄较大且疾病及毒性严重程度更高，但CAR T细胞治疗后的ICU死亡率仍然较低。

### 第二部分 AI 大师评价

本研究为多中心回顾性队列分析，系统评估了2018至2023年CAR T细胞治疗患者的ICU入院趋势及结局。结果显示，尽管患者年龄和合并症负担增加，毒性更重，但ICU入院率显著下降且死亡率仍维持低水平。研究凸显了CAR T治疗支持管理的优化和早期干预策略的成熟。创新性在于长期趋势分析与毒性管理策略演变的量化识别，但受限于回顾性设计及中心间差异。

---

## 3. STARRT-AKI 试验期间不良血流动力学事件相关因素的事后次级分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41466322)
**期刊：** Critical care (London, England)
**PMID：** 41466322
**DOI：** 10.1186/s13054-025-05693-0

### 第一部分 原文与翻译

**英文原标题：** Factors associated with adverse haemodynamic events during the STARRT-AKI trial: a post-hoc secondary analysis.

> **英文摘要：**
> INTRODUCTION: Haemodynamic adverse events related to renal replacement therapy are a complication of all RRT modalities used in the ICU, including intermittent haemodialysis (IHD), sustained low efficiency dialysis (SLED) and continuous renal replacement therapy (CRRT). At present it is unclear which risk factors predispose to HAE and whether these contribute to adverse patient outcomes.
> 
> METHODS: We performed a secondary analysis of the multinational STARRT-AKI trial to assess factors associated with the occurrence of haemodynamic adverse events (HAE) in patients receiving RRT and whether these HAE were associated with less favourable clinical outcomes. The primary analysis was a multivariable Cox proportional hazards model based on the least absolute shrinkage and selection operator (LASSO), which included time to HAE as the dependent variable.
> 
> RESULTS: Factors significantly associated with an increased hazard ratio (HR) for HAE during RRT were a higher SOFA score at RRT initiation (HR 1.05; 95% 1.00-1.10), use of IHD as the initial RRT modality in comparison to CRRT (HR 1.74; 95% CI 1.28-2.37) and use of SLED as the initial RRT modality in comparison to CRRT (HR 2.73; 95% CI 1.65-4.51). In a multivariable analysis, adjusted for baseline patient characteristics and RRT initiation covariates, there was no significant association between the occurrence of a HAE during RRT and mortality, dialysis dependence, length of stay, RRT-free days, ventilator-free days or vasoactive-free days, respectively. There was, however, a significant association between multiple haemodynamic adverse events and all-cause mortality at 90 days.
> 
> CONCLUSIONS: In this secondary analysis of the STARRT-AKI trial, the use of intermittent RRT modalities and higher severity of illness were associated with HAE during RRT. These events were not significantly associated with adverse clinical outcomes, apart from a significant association between multiple HAE and all-cause mortality at 90 days.

> **中文摘要：**
> 引言：与肾脏替代治疗相关的血流动力学不良事件是重症监护病房中所有RRT模式的并发症，包括间歇性血液透析（IHD）、持续低效透析（SLED）和连续性肾脏替代治疗（CRRT）。目前尚不清楚哪些风险因素易导致血流动力学不良事件（HAE），以及这些事件是否会影响患者的不良结局。
> 
> 方法：我们对多国联合STARRT-AKI试验进行了次级分析，以评估接受RRT治疗的患者中，与血流动力学不良事件（HAE）发生相关的因素，以及这些事件是否与不良临床结局相关。主要分析采用基于最小绝对收缩与选择算子（LASSO）的多变量Cox比例风险模型，以HAE发生时间为因变量。
> 
> 结果：在RRT期间，与HAE风险比（HR）升高显著相关的因素包括：RRT开始时较高的SOFA评分（HR 1.05；95% CI 1.00–1.10）、以间歇性血液透析（IHD）作为初始RRT模式（相较于CRRT，HR 1.74；95% CI 1.28–2.37），以及以SLED作为初始RRT模式（相较于CRRT，HR 2.73；95% CI 1.65–4.51）。在调整基线患者特征及RRT启动相关协变量后的多变量分析中，HAE的发生与死亡率、透析依赖、住院时长、无RRT天数、无呼吸机天数或无血管活性药物天数之间均无显著关联。然而，多次发生HAE与90天全因死亡率之间存在显著关联。
> 
> 结论：在STARRT-AKI试验的次级分析中，使用间歇性RRT模式以及较高病情严重程度与RRT期间HAE的发生相关。这些事件总体上未与不良临床结局显著相关，但多次HAE的发生与90天全因死亡率存在显著关联。

### 第二部分 AI 大师评价

本研究基于STARRT-AKI试验数据，对重症患者接受不同RRT模式时血流动力学不良事件的风险因素进行了深入分析。结果揭示了间歇性RRT模式与较高SOFA评分均增加HAE的发生风险，但单次HAE似乎并未显著影响临床结局。值得注意的是，多次HAE与90天全因死亡率呈正相关。该研究为RRT方式选择与风险评估提供了重要证据，但受限于事后分析设计与模型变量限制，仍需前瞻性研究加以验证。

---

## 4. 揭示连续肾脏替代治疗中柠檬酸盐积聚的真正决定因素：被忽视的柠檬酸盐浓度与稀释方式的作用。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41462329)
**期刊：** Critical care (London, England)
**PMID：** 41462329
**DOI：** 10.1186/s13054-025-05816-7

### 第一部分 原文与翻译

**英文原标题：** Unraveling the true determinants of citrate accumulation in continuous kidney replacement therapy: the overlooked role of citrate concentration and dilution modality.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本研究聚焦于连续肾脏替代治疗（CKRT）中柠檬酸盐积聚这一关键问题，强调了此前研究中被低估的两个因素——柠檬酸盐浓度和稀释模式。文章旨在澄清实际影响柠檬酸盐代谢与积聚风险的生理与操作变量，为临床个体化优化抗凝策略提供理论依据。尽管尚未知具体实验设计与结果，但其研究思路具较强创新性，可能推动CKRT安全性与精准管理的新方向。

---

## 5. 心脏骤停后自动化灰白质比值的纵向评估及其预后预测价值

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41462324)
**期刊：** Critical care (London, England)
**PMID：** 41462324
**DOI：** 10.1186/s13054-025-05762-4

### 第一部分 原文与翻译

**英文原标题：** Longitudinal assessment of automated gray-white matter ratio for outcome prediction after cardiac arrest.

> **英文摘要：**
> BACKGROUND: The gray-white matter ratio (GWR) on head CT is a well-established marker of hypoxic-ischemic brain injury after cardiac arrest, but its prognostic performance may vary with the timing of imaging. We aimed (i) to evaluate the prognostic value of GWR across serial CT scans within the same comatose patients, and (ii) to determine whether the longitudinal changes of GWR provide additional prognostic information beyond single time-point measurements.
> 
> METHODS: We prospectively recruited 123 comatose patients with cardiac arrest admitted to three intensive care units. All patients underwent serial non-contrast head CT at three predefined time windows (< 24 h, 24-96 h, and 96-168 h after cardiac arrest). GWR values were automatically calculated using an atlas-based approach. Neurological outcome at 3 months was assessed with the Cerebral Performance Category score (CPC) and dichotomized into good (CPC 1-2) or poor (CPC 3-5). GWR values and their progression were compared between outcome groups. Prognostic accuracy of GWR at each time window was assessed using receiver operating characteristic (ROC) analysis.
> 
> RESULTS: GWR was consistently lower in patients with poor outcomes compared to those with good outcomes across all time windows (for all p < 0.001). In poor-outcome patients, GWR declined after the first 24 h, whereas it was stable in good-outcome patients. The prognostic performance of GWR improved with later imaging, with an AUC of 0.72 (95% CI 0.62-0.81) at < 24 h, 0.78 (95% CI 0.69-0.86) at 24-96 h, and 0.81 (95% CI 0.72-0.88) at 96-168 h after cardiac arrest. Incorporating longitudinal changes in GWR slightly improved prediction, with the AUC increasing from 0.81 to 0.83 at 96-168 h.
> 
> CONCLUSIONS: Automated GWR is a useful predictor of outcome after cardiac arrest, with higher accuracy on delayed CT (> 24 h). The different GWR progression trajectories between patients with poor and good outcomes suggest that longitudinal CT assessments may provide additional prognostic information.

> **中文摘要：**
> 背景：头部CT上的灰白质比值（GWR）是心脏骤停后缺氧缺血性脑损伤的公认指标，但其预后性能可能随影像检查时间而变化。本研究旨在（i）评估同一昏迷患者不同时期连续CT检查中GWR的预后价值；（ii）确定GWR的纵向变化是否在单一时间点测量之外提供额外的预后信息。
> 
> 方法：我们前瞻性纳入了在三家重症监护室收治的123例心脏骤停昏迷患者。所有患者均在三个预设时间窗（＜24小时、24–96小时和96–168小时）进行了序列非增强头部CT检查。采用基于脑图谱的自动化方法计算GWR值。3个月时使用脑功能分级（Cerebral Performance Category，CPC）评估神经学结局，并将其分为良好结局（CPC 1–2）和不良结局（CPC 3–5）。比较不同结局组的GWR数值及其变化趋势，并利用受试者工作特征曲线（ROC）分析评估各时间窗GWR的预后准确性。
> 
> 结果：在所有时间窗内，不良结局患者的GWR均显著低于良好结局患者（所有p＜0.001）。不良结局患者的GWR在前24小时后进一步下降，而良好结局患者则保持稳定。随着影像时间推迟，GWR的预后性能提高：＜24小时的AUC为0.72（95% CI 0.62–0.81），24–96小时为0.78（95% CI 0.69–0.86），96–168小时为0.81（95% CI 0.72–0.88）。纳入GWR的纵向变化后，预测性能略有改善，在96–168小时AUC由0.81上升至0.83。
> 
> 结论：自动化GWR是心脏骤停后预后评估的有用指标，延迟CT（＞24小时）可获得更高预测准确度。良好与不良结局患者之间GWR的不同变化轨迹提示，纵向CT评估可能提供额外的预后信息。

### 第二部分 AI 大师评价

本研究系统评估了心脏骤停后昏迷患者在不同时间窗内自动化灰白质比值（GWR）的动态变化及其预后价值。通过多中心前瞻性设计和自动化影像分析，揭示了不良结局患者GWR随时间下降、良好结局患者稳定的规律。研究发现延迟CT的预测准确性更高，并且纵向变化能轻微提升预测性能，提示动态影像指标较单时点测量更具临床价值。研究创新性地引入自动化处理与时间维度分析，但仍需更大样本验证以优化具体临床应用。

---

## 6. 耐药性、异质耐药性及适应性代价共同导致胶质素治疗肺炎失败

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41461032)
**期刊：** Proceedings of the National Academy of Sciences of the United States of America
**PMID：** 41461032
**DOI：** 10.1073/pnas.2515303123

### 第一部分 原文与翻译

**英文原标题：** Resistance, heteroresistance, and fitness costs drive colistin treatment failure during  pneumonia.

> **英文摘要：**
> is an , , , , , and  species (ESKAPE) pathogen linked to healthcare-associated diseases. Due to evolved resistance, last-resort antibiotics such as the lipooligosaccharide (LOS)-targeting colistin are increasingly used to treat multidrug-resistant isolates. To track the evolution of colistin resistance within a host, we performed sequential oropharyngeal infections in immunocompetent or immune-depleted mice in the presence of inhaled colistin. Both resistant and heteroresistant  strains emerged with  mutations that efficiently competed with the susceptible parent in the presence of colistin. These  mutants had a fitness cost in the absence of colistin treatment but retained their ability to colonize the host. In contrast, LOS-deficient  mutants removed the target of colistin, but such mutants were unable to colonize the lung. The two pathogenic  mutants showed clear evidence of LOS modification, which was linked to increased transcription of LOS modification enzymes, including the product of the cryptic  gene. Spontaneous insertion mutations that caused hyperexpression of  allowed the heteroresistant mutant to develop clinically significant colistin resistance. Insertion mutations upstream of the  gene or those disrupting , which encodes a small histone-like protein, resulted in increased  transcript, linking expression of this protein to clinically significant resistance. A resistant variant derived from the heteroresistant parent was stable in the absence of drug, but continued passaging selected for colistin-resensitized pseudorevertants that were largely due to disruption of the LOS modification enzymes. Therefore, colistin heteroresistance is an early stage in the stepwise acquisition of stable colistin resistance in .

> **中文摘要：**
> 是一种属于ESKAPE病原体群的革兰阴性菌，与医疗相关感染密切相关。由于其演化出的耐药性，作为“最后防线”抗生素的靶向脂寡糖（LOS）的多黏菌素（colistin）正被越来越多地用于治疗多重耐药菌株。为了追踪宿主体内colistin耐药性的演化，我们在吸入colistin的条件下，于免疫健全或免疫受损小鼠中进行了连续的口咽感染实验。结果显示，在colistin存在的情况下，出现了携带突变的耐药菌株和异质耐药菌株，这些突变株在药物存在时可与易感亲本高效竞争。这些突变株在缺乏药物治疗时表现出适应性代价，但仍保持其定植宿主的能力。相比之下，缺乏LOS的突变株虽然去除了colistin的作用靶点，但失去了定植肺部的能力。两种致病性突变株显示出明显的LOS修饰证据，这与LOS修饰酶转录水平的升高有关，其中包括隐匿基因产物的表达。自发的插入突变导致的基因过度表达，使异质耐药突变株获得了临床显著的colistin耐药性。发生在某基因上游的插入突变或破坏编码小型类组蛋白的基因，也会使该基因的转录水平升高，从而将这种蛋白的表达与临床显著的耐药性联系起来。源自异质耐药亲本的耐药变异株在无药物条件下仍保持稳定，但连续传代后出现了对colistin重新敏感的假返祖突变，主要由于LOS修饰酶功能的破坏所致。因此，colistin的异质耐药性是获得稳定colistin耐药性的早期阶段。

### 第二部分 AI 大师评价

本研究聚焦于多黏菌素在治疗肺部感染过程中耐药性及异质耐药性的动态演化机制。作者通过小鼠模型的连续感染实验，揭示了耐药性突变的竞争优势及其适应性代价，并确认了LOS修饰途径在耐药形成中的关键作用。研究创新性地确定了异质耐药向稳定耐药转变的分子机制，为理解多黏菌素治疗失败提供了重要线索。其局限性在于模型系统与临床环境间可能存在差异，需进一步验证其临床相关性。

---

速递结束，祝您工作愉快！